Elevating clinical research — from the bench to the boardroom

Bridging bench science and clinical excellence

With over 14 years of clinical operations leadership, Padma brings deep expertise in Phase I–III global trials across oncology, rare diseases, inflammation, and metabolic disorders.

She has driven studies at Amgen, Gilead, Pharmacyclics (AbbVie), Revolution Medicines, and Biomea Fusion — from IND-enabling activities through site activation, enrollment, and closeout. Her work contributed to the FDA approval of Ibrutinib in MZL and the $22 billion AbbVie acquisition of Pharmacyclics.

Padma founded Nava Clinical Solutions to bring this expertise directly to organizations and professionals who need it most.